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Background: Diabetes complications markedly impact patient survival, quality of life and healthcare costs. Effective treatments and interventions 
reduce such burden and improve quality of care. Benchmarking (Bm) incorporates two-sided feedback of a physician’s individual performance 
graded alongside the current mean achievement of a peer group, as well as patient’s target attainment. This study assessed the effect of Bm on 
quality of care in type 2 diabetes outpatients over a 12 mth follow-up (FU) period.
Methods: Optimise is a non-interventional, observational study conducted in 6 European countries (NCT00681850). Physicians were randomly 
assigned to either a Bm or control (Co) group. The primary endpoint was the percentage of patients achieving pre-set targets according to European 
guidelines (2007) for HbA1c (<7%), low-density lipoprotein cholesterol (LDL-C <80 mg/dL Belgium, <100 mg/dl all other countries) and systolic 
blood pressure (<130 mmHg). The LDL-C results are presented here.
Results:  2487 patients were randomized to the Bm and 1503 to the Co group by 368 investigators (229 Bm, 139 Co). Both groups were highly 
comparable regarding all baseline demographic, anthropometric and diabetes-related parameters. At baseline, 66.5% (2654/3989) of patients were 
taking lipid-lowering drugs, predominantly statins (93.1%, 2470/2654), which increased to 74.0% (2579/3487) after 12 mth FU (statins 93.8%, 
2419/2579). The most frequently used statins and dosage were: simvastatin (39.9%, 966/2419) 20 mg/day (46.5%, 449/966); rosuvastatin 
(27.5%, 664/2419) 10 mg/day (75.5%, 501/664); and atorvastatin (24.7%, 598/2419) 20 mg/day (47.3%, 283/598). LDL-C decreased in both 
groups after 12 mth FU: Bm -5.93% (95% CI -7.83%; -4.02%), Co -1.94% (-4.42%; 0.54%). After 12 mth FU, 1853 patients (Bm 953, Co 900) 
attained LDL-C <80 mg/dl target and 1544 (Bm 1121, Co 423) LDL-C <100 mg/dl target. Bm increased the frequency of patients achieving LDL-C 
target after 12 mth FU vs Co (63.2%, 1310/2074 vs 56.8%, 751/1323).
Conclusion:  Despite statin use, control of LDL-C needs to be improved. The OPTIMISE results indicate that benchmarking had a positive effect on 
LDL-C target attainment in type 2 diabetic patients.
